The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ormaplatine     (1R,2R)-cyclohexane-1,2- diamine;...

Synonyms: Ormaplatino, Ormaplatinum, UNII-SFK1SGY8V1
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Tetraplatin


High impact information on Tetraplatin


Chemical compound and disease context of Tetraplatin


Biological context of Tetraplatin


Anatomical context of Tetraplatin


Associations of Tetraplatin with other chemical compounds

  • The diaminocyclohexane platinum (Pt(DACH)) derivatives ormaplatin and oxaliplatin have caused severe and dose-limiting peripheral sensory neurotoxicity in a clinical trial [10].
  • The accumulation of ormaplatin was not inhibited by ouabain in either of the cell lines [11].
  • Of the CDDP analogues tested, including carboplatin (CBDCA), [(glycolate-0,0') diammineplatinum (II) (254-S)], ormaplatin [tetrachloro-(d,1-trans)- 1,2-diaminocyclohexaneplatinum (IV) (OP)] and oxaliplatin [oxalato (trans-1-1,2-diaminocyclohexane) platinum (II) (1-OHP)], no agent showed superior antitumor activity compared to CDDP [12].

Gene context of Tetraplatin

  • However, the accumulation of ormaplatin in PC-14/CDDP was almost the same as that in PC-14 [11].

Analytical, diagnostic and therapeutic context of Tetraplatin


  1. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin. Parker, R.J., Vionnet, J.A., Bostick-Bruton, F., Reed, E. Cancer Res. (1993) [Pubmed]
  2. Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model. Luo, F.R., Wyrick, S.D., Chaney, S.G. Cancer Chemother. Pharmacol. (1999) [Pubmed]
  3. Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma. Thompson, D.C., Wyrick, S.D., Holbrook, D.J., Chaney, S.G. Cancer Res. (1995) [Pubmed]
  4. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt, W., Chaney, S.G. Cancer Res. (1993) [Pubmed]
  5. Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812). Tutsch, K.D., Arzoomanian, R.Z., Alberti, D., Tombes, M.B., Feierabend, C., Robins, H.I., Spriggs, D.R., Wilding, G. Investigational new drugs. (1999) [Pubmed]
  6. Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). O'Rourke, T.J., Weiss, G.R., New, P., Burris, H.A., Rodriguez, G., Eckhardt, J., Hardy, J., Kuhn, J.G., Fields, S., Clark, G.M. Anticancer Drugs (1994) [Pubmed]
  7. Organ-specific biotransformation of ormaplatin in the Fischer 344 rat. Thompson, D.C., Vaisman, A., Sakata, M.K., Wyrick, S.D., Holbrook, D.J., Chaney, S.G. Cancer Chemother. Pharmacol. (1995) [Pubmed]
  8. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats. Luo, F.R., Wyrick, S.D., Chaney, S.G. Cancer Chemother. Pharmacol. (1999) [Pubmed]
  9. DNA sequence selectivity of cisplatin analogues in intact human cells. Murray, V., Whittaker, J., McFadyen, W.D. Chem. Biol. Interact. (1998) [Pubmed]
  10. Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Screnci, D., Er, H.M., Hambley, T.W., Galettis, P., Brouwer, W., McKeage, M.J. Br. J. Cancer (1997) [Pubmed]
  11. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Ohmori, T., Morikage, T., Sugimoto, Y., Fujiwara, Y., Kasahara, K., Nishio, K., Ohta, S., Sasaki, Y., Takahashi, T., Saijo, N. Jpn. J. Cancer Res. (1993) [Pubmed]
  12. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. Fukuda, M., Ohe, Y., Kanzawa, F., Oka, M., Hara, K., Saijo, N. Anticancer Res. (1995) [Pubmed]
  13. Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells. Kido, Y., Khokhar, A.R., Siddik, Z.H. Biochem. Pharmacol. (1994) [Pubmed]
  14. Solution chemistry and analytical characterization of ormaplatin. Northcott, S.E., Marr, J.G., Secreast, S.L., Han, F., Dezwaan, J. Journal of pharmaceutical and biomedical analysis. (1991) [Pubmed]
  15. Gene-specific damage produced by cisplatin, ormaplatin and UV light in human cells as assayed by the polymerase chain reaction. Oshita, F., Eastman, A. Oncol. Res. (1993) [Pubmed]
  16. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin. Figg, W.D., Christian, M.C., Lush, R., Link, C.J., Davis, P., Kohn, E., Sarosy, G., Rothenberg, M.L., Weiss, R.B., Ryan, N., Jacobs, J., Reed, E. Biopharmaceutics & drug disposition. (1997) [Pubmed]
WikiGenes - Universities